RNA
NASDAQ
US
Avidity Biosciences, Inc. - Common Stock
Healthcare
· Biotechnology
· IPO Feb 2026
$13.44
▼ $-0.03
(-0.22%)
Vol 282K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$10.9B
ROE
-37.7%
Margin
-2634.6%
D/E
0.00
Beta
0.91
52W
$22–$73
Wall Street Consensus
5 analysts · Apr 20261
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
80.0%
Buy Rating
Price Chart
Similar Stocks
TENX
Tenax Therapeutics Inc
$76.1M
IKT
Inhibikase Therapeutics Inc
$248.6M
KROS
Keros Therapeutics Inc
P/E 9.6
$620.3M
VYGR
Voyager Therapeutics Inc
$218.5M
ELDN
Eledon Pharmaceuticals Inc
$113.4M
CAMP
CAMP4 Therapeutics Corp
$318.0M
NERV
Minerva Neurosciences Inc
$28.1M
ARCT
Arcturus Therapeutics Holdings Inc
$174.2M
FENC
Fennec Pharmaceuticals Inc
$262.9M
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -33.5% | -33.5% | -33.5% | -33.5% | -37.7% | -37.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -4089.3% | -4247.8% | -4247.8% | -4247.8% | -2634.6% | -2634.6% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.26 | 9.26 | 9.26 | 9.26 | 11.57 | 11.57 |
Key Ratios
ROA (TTM)
-33.7%
P/S (TTM)
521.06
P/B
2.4
EPS (TTM)
$-4.17
CF/Share
$-2.93
Rev Growth 3Y
+5.3%
52W High
$72.61
52W Low
$21.51
$21.51
52-Week Range
$72.61
How does RNA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RNA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
521.1
▲
3955%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
2.4
▼
1%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RNA profitability vs Biotechnology peers
ROE
-37.7%
▲
44%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-2634.6%
▼
819%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-33.7%
▲
28%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
RNA financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
11.6
▲
161%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.9
▼
6%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
RNA fundamentals radar
RNA
Peer median
Industry
RNA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
RNA vs peers: key metrics
Latest News
International Stocks Are Trouncing Growth Stocks and This ETF Pays You a …
Yahoo Finance · Apr 05
Jim Cramer Discusses Starbucks (SBUX) CEO’s Turnaround Algorithm
Yahoo Finance · Apr 05
Nike Takes 'Intentional' Hit To Clear 'Unhealthy Inventory' In Q3 As CEO …
Yahoo Finance · Apr 04
March jobs report: US economy adds 178,000 jobs, unemployment rate falls to …
Yahoo Finance · Apr 03
BIO-key International, Inc. Q4 2025 Earnings Call Summary
Yahoo Finance · Apr 03